Abstract
A prospective, phase II clinical study of tislelizumab monotherapy or in combination with lenvatinib for neoadjuvant treatment of resectable hepatocellular carcinoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have